. home.aspx



Prostate cancer mutation found to triple risk of death

May 07, 2019 / Anna Smith

The largest ever study of advanced prostate cancer genomics has revealed that men with mutations in the retinoblastoma gene in their tumours were more than three times as likely to die and nearly seven times as likely to relapse on standard treatments as those without the gene. Scientists identified the gene mutation in the tumours of men, which could help to pick out patients for more intensive treatment in the future. The gene in question – the retinoblastoma gene – is known as RB1 because mutations in it cause a rare children’s eye cancer of the same name and is known to play a central role in stopping healthy cells from dividing uncontrollably. Professor Johann de Bono, Regius Professor of cancer research at The Institute of Cancer Research, London, and consultant medical oncologist at The Royal Marsden NHS Foundation trust, said that the study “really got under the bonnet of prostate cancer to understand the ‘engine’ driving tumour growth and ex...